Amdocs (DOX) moved into focus after VEON announced a 10 year technology agreement in which Amdocs will modernize VEON's core operations and integrate QazCode's AI capabilities into its aOS telecom platform.
The VEON agreement hit just as momentum in Amdocs’ stock has been rebuilding, with a 1-day share price return of 2.56% and a 90-day share price return of 16.06% from a last close of US$60.25. That short-term strength contrasts with a weaker backdrop, where the year-to-date share price return is down 24.84% and the 1-year total shareholder return has declined 23.62%. As a result, this contract appears to be one of the clearer recent catalysts shifting sentiment toward the business.
Scan how other telecom and AI-focused platforms are reacting to deals like Amdocs’ VEON partnership by reviewing our hand-picked 92 AI infrastructure stocks.
So after Amdocs’ sharp rebound on the VEON news and a longer stretch of weaker returns, does it make more sense to lean in now or wait for a cheaper entry before the next move in sentiment?
Most Popular Narrative: 26.6% Undervalued
Amdocs is framed as undervalued in the most followed narrative, with a fair value of $82.03 versus the recent share price near $60.25. This comparison puts the VEON deal into a very different light for anyone focused on long term cash flows.
Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services, which account for approximately 65% of total revenue, and a substantial 12-month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases.
See why 41 investors see Amdocs as 27% undervalued.
Result: Fair Value of $82.03 (UNDERVALUED)
Still, Amdocs’ thesis could be tested if telecom clients slow spending on large IT projects or if GenAI investments fail to convert into profitable contracts.
Find out about the key risks to this Amdocs narrative.
Next Steps
If this mix of opportunity and concern around Amdocs leaves you on the fence, quickly review the numbers and context directly. Then weigh both the potential upside and downside through the 4 key rewards and 1 important warning sign.
Looking for more Amdocs sized investment ideas?
If Amdocs has sharpened your appetite for opportunities, do not stop here. Cast a wider net and let data driven shortlists guide your next move.
- Target potential mispricings by scanning companies that combine solid fundamentals with room for a re rate using the 27 high quality undervalued stocks.
- Reinforce your portfolio’s foundation by focusing on businesses built on stronger finances through the list of solid balance sheet and fundamentals (25 results).
- Hunt for under the radar opportunities with robust metrics that bigger funds may have overlooked by starting with the 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com